Molecular & Cellular Toxicology

  • 제3권2호
  • /
  • Pages.137-144
  • /
  • 2007
  • /
  • 1738-642X(pISSN)
  • /
  • 2092-8467(eISSN)
대한독성유전 단백체학회 (The Korean Society of Toxicogenomics and Toxicoproteomics)
권호 표지

Gene Expression Profiling of Doxifluridine Treated Liver, Small and Large Intestine in Cynomolgus (Macaca fascicularis) Monkeys

  • 발행 : 2007.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The mechanism of cytotoxicity of doxifluridine, a prodrug fluorouracil (5-FU), has been ascribed to the misincorporation of fluoropyrimidine into RNA and DNA and to the inhibition of the nucleotide synthetic enzyme thymidylate synthase. Increased understanding of the mechanism of 5-FU has led to the development of strategies that increases its anticancer activity or predicts its sensitivity to patients. Using GeneChip?? Rhesus Macaque Genome arrays, we analyzed gene expression profiles of doxifluridine after two weeks repeated administration in cynomolgus monkey. Kegg pathway analysis suggested that cytoskeletal rearrangement and cell adhesion remodeling were commonly occurred in colon, jejunum, and liver. However, expression of genes encoding extracellular matrix was distinguished colon from others. In colon, COL6A2, COL18A1, ELN, and LAMA5 were over-expressed. In contrast, genes included in same category were down-regulated in jejunum and liver. Interestingly, MMP7 and TIMP1, the key enzymes responsible for ECM regulation, were overexpressed in colon. Several studies were reported that both gene reduced cell sensitivity to chemotherapy-induced apoptosis. Therefore, we suggest they have potential as target for modulation of 5-FU action. In addition, the expression of genes which have been previously known to involve in 5-FU pathway, were examined in three organs. Particularly, there were more remarkable changes in colon than in others. In colon, ECGF1, DYPD, TYMS, DHFR, FPGS, DUT, BCL2, BAX, and BAK1 except CAD were expressed in the direction that was good response to doxifluridine. These results may provide that colon is a prominent target of doxifluridine and transcriptional profiling is useful to find new targets affecting the response to the drug.

키워드

참고문헌

  1. Salonga, D. et al. Colorectal tumors responding to 5- fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6: 1322-1327 (2000)
  2. Terashima, M. et al. Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to doxifluridine in gastric cancer patients. Eur. J. Cancer 38:2375-2381 (2002) https://doi.org/10.1016/S0959-8049(02)00380-5
  3. Giacchetti, S. et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracilleucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18:136-147 (2000) https://doi.org/10.1200/JCO.2000.18.1.136
  4. Douillard, J. Y. et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041-1047 (2000) https://doi.org/10.1016/S0140-6736(00)02034-1
  5. Allegra, C. J. et al. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J. Clin. Oncol. 20:1735-1743 (2002) https://doi.org/10.1200/JCO.2002.07.080
  6. Mader, R. M., Muller, M. & Steger, G. G. Resistance to 5-fluorouracil. Gen. Pharmacol. 31(5):661-666 (1998) https://doi.org/10.1016/S0306-3623(98)00191-8
  7. Longley, D. B., Harkin, D. P. & Johnston, P. G. 5- fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3:330-338 (2003) https://doi.org/10.1038/nrc1074
  8. Schmidt, W. M. et al. Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling. Int. J. Cancer 112(2):200-212 (2004) https://doi.org/10.1002/ijc.20401
  9. Kidd, E. A. et al. Variance in the expression of 5- Fluorouracil pathway genes in colorectal cancer. Clin. Cancer Res. 11(7):2612-2619 (2005) https://doi.org/10.1158/1078-0432.CCR-04-1258
  10. Kono, A. et al. Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chemo. Pharm. Bull. 31:175-178 (1983) https://doi.org/10.1248/cpb.31.175
  11. Hasegawa, S. et al. Thymidine phosphorylase expression and efficacy of adjuvant doxifluridine in advanced colorectal cancer patients. Oncol. Rep. 13(4):621- 626 (2005)
  12. Kornmann, M. et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin. Cancer Res. 9(11):4116-4124 (2003)
  13. Sohn, K. J. et al. Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate. Gut. 53(12):1825-1831 (2004) https://doi.org/10.1136/gut.2004.042713
  14. O'Dwyer, P. J. et al. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. Clin. Oncol. 8(9):1497- 1503 (1990) https://doi.org/10.1200/JCO.1990.8.9.1497
  15. Boudreau, N., Werb, Z. & Bissell, M. J. Suppression of apoptosis by basement membrane requires threedimensional tissue organization and withdrawal from the cell cycle. Proc. Natl. Acad. Sci. USA 93(8):3509- 3513 (1996)
  16. Jinawath, N. et al. Comparison of gene-expression profiles between diffuse-and intestinal-type gastric cancers using a genome-wide cDNA microarray. Oncogene 23(40):6830-6844 (2004) https://doi.org/10.1038/sj.onc.1207886
  17. Yamamoto, H., Itoh, F., Hinoda, Y. & Imai, K. Suppression of matrilysin inhibits colon cancer cell invasion in vitro. Int. J. Cancer 61:218-222 (1995) https://doi.org/10.1002/ijc.2910610213
  18. Miyazaki, K. et al. Matrilysin as a target for chemotherapy for colon cancer: use of antisense oligonucleotides as antimetastatic agents. Cancer Chemother. Pharmacol. 43:S52-55 (1999) https://doi.org/10.1007/s002800051098
  19. Ohtani, Y. et al. Suppression effects of human recombinant tissue inhibitor of metalloproteinases-1(TIMP- 1) on tumor proliferation using in vivo treatment model of well-differentiated colon cancer cell line, HT29. Acta Med. Okayama. 60(5):257-266 (2006)
  20. Davidsen, M. L. et al. TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Br. J. Cancer 95(8):1114-1120 (2006) https://doi.org/10.1038/sj.bjc.6603378
  21. Fingleton, B., Vargo-Gogola, T., Crawford, H. C. & Matrisian. L. M. Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 3(6):459-468 (2001) https://doi.org/10.1038/sj.neo.7900190
  22. Sethi, T. et al. Extracellular matrix proteins protect small cell lung cancer against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 5:662-668 (1999) https://doi.org/10.1038/9511
  23. Taylor, S. T., Hickman, J. A. & Dive, C. Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors. J. Natl. Cancer Inst. 92:18-23 (2000) https://doi.org/10.1093/jnci/92.1.18
  24. Liu, J. J. et al. Heparin/heparan sulfate interacting protein plays a role in apoptosis induced by anticancer drugs. Carcinogenesis 25(6):873-879 (2004) https://doi.org/10.1093/carcin/bgh081